These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36633470)

  • 1. Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies.
    Curry MP; Vargas HE; Befeler AS; Pyrsopoulos NT; Patwardhan VR; Jamil K
    Hepatol Commun; 2023 Jan; 7(1):e1307. PubMed ID: 36633470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
    Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
    Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terlipressin for hepatorenal syndrome.
    Wong F
    Curr Opin Gastroenterol; 2024 May; 40(3):156-163. PubMed ID: 38353275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
    Wong F; Pappas SC; Curry MP; Reddy KR; Rubin RA; Porayko MK; Gonzalez SA; Mumtaz K; Lim N; Simonetto DA; Sharma P; Sanyal AJ; Mayo MJ; Frederick RT; Escalante S; Jamil K;
    N Engl J Med; 2021 Mar; 384(9):818-828. PubMed ID: 33657294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
    Sharma P; Kumar A; Shrama BC; Sarin SK
    Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
    Sagi SV; Mittal S; Kasturi KS; Sood GK
    J Gastroenterol Hepatol; 2010 May; 25(5):880-5. PubMed ID: 20074149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
    Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
    J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin.
    Weinberg EM; Wong F; Vargas HE; Curry MP; Jamil K; Pappas SC; Sharma P; Reddy KR
    Liver Transpl; 2024 Apr; 30(4):347-355. PubMed ID: 37801553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome.
    Moore K; Jamil K; Verleger K; Luo L; Kebede N; Heisen M; Corman S; Leonardi R; Bakker R; Maï C; Shamseddine N; Huang X; Allegretti AS
    Aliment Pharmacol Ther; 2020 Jul; 52(2):351-358. PubMed ID: 32495956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.
    Boyer TD; Sanyal AJ; Garcia-Tsao G; Blei A; Carl D; Bexon AS; Teuber P;
    J Hepatol; 2011 Aug; 55(2):315-21. PubMed ID: 21167235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.
    Sanyal AJ; Boyer T; Garcia-Tsao G; Regenstein F; Rossaro L; Appenrodt B; Blei A; Gülberg V; Sigal S; Teuber P;
    Gastroenterology; 2008 May; 134(5):1360-8. PubMed ID: 18471513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
    Fabrizi F; Dixit V; Messa P; Martin P
    Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.
    Halimi C; Bonnard P; Bernard B; Mathurin P; Mofredj A; di Martino V; Demontis R; Henry-Biabaud E; Fievet P; Opolon P; Poynard T; Cadranel JF
    Eur J Gastroenterol Hepatol; 2002 Feb; 14(2):153-8. PubMed ID: 11981339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome.
    Wong F; Boyer TD; Sanyal AJ; Pappas SC; Escalante S; Jamil K
    Nephrol Dial Transplant; 2020 Sep; 35(9):1554-1561. PubMed ID: 30887050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terlipressin in combination with albumin as a therapy for hepatorenal syndrome in patients aged 65 years or older.
    Mujtaba MA; Gamilla-Crudo AK; Merwat SN; Hussain SA; Kueht M; Karim A; Khattak MW; Rooney PJ; Jamil K
    Ann Hepatol; 2023; 28(5):101126. PubMed ID: 37302573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
    Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
    J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terlipressin therapy for renal failure in cirrhosis.
    Triantos CK; Samonakis D; Thalheimer U; Cholongitas E; Senzolo M; Marelli L; Leandro G; Patch D; Burroughs AK
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
    Solanki P; Chawla A; Garg R; Gupta R; Jain M; Sarin SK
    J Gastroenterol Hepatol; 2003 Feb; 18(2):152-6. PubMed ID: 12542598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.